MedPath

湖南恒生制药股份有限公司

Ownership
-
Established
2001-09-17
Employees
-
Market Cap
-
Website
www.hnhszy.com/

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

167

NMPA:167

Drug Approvals

Dopamine Hydrochloride Injection

Product Name
盐酸多巴胺注射液
Approval Number
国药准字H20254504
Approval Date
Jun 10, 2025
NMPA

Dopamine Hydrochloride Injection

Product Name
盐酸多巴胺注射液
Approval Number
国药准字H20254503
Approval Date
Jun 10, 2025
NMPA

Pitavastatin Calcium Tablets

Product Name
匹伐他汀钙片
Approval Number
国药准字H20243843
Approval Date
May 28, 2024
NMPA

Colloidal Bismuth Pectin Capsules

Product Name
胶体果胶铋胶囊
Approval Number
国药准字H20193147
Approval Date
Apr 29, 2024
NMPA

柴黄片

Approval Number
国药准字Z20093271
Approval Date
Apr 29, 2024
NMPA

安乐片

Approval Number
国药准字Z20093303
Approval Date
Apr 29, 2024
NMPA

舒胸片

Approval Number
国药准字Z20093368
Approval Date
Apr 29, 2024
NMPA

Cefmetazole Sodium for Injection

Product Name
注射用头孢美唑钠
Approval Number
国药准字H20234477
Approval Date
Nov 14, 2023
NMPA

Cefmetazole Sodium for Injection

Product Name
注射用头孢美唑钠
Approval Number
国药准字H20234478
Approval Date
Nov 14, 2023
NMPA

Milrinone Injection

Product Name
米力农注射液
Approval Number
国药准字H20234350
Approval Date
Oct 24, 2023
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 17
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.